Hills Bank & Trust Co reduced its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 39.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 42,030 shares of the biopharmaceutical company’s stock after selling 27,290 shares during the quarter. Hills Bank & Trust Co’s holdings in Pfizer were worth $1,047,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Y Intercept Hong Kong Ltd acquired a new position in Pfizer during the third quarter valued at approximately $3,019,000. Kepler Cheuvreux Suisse SA acquired a new position in Pfizer during the third quarter valued at approximately $16,613,000. Money Concepts Capital Corp boosted its position in Pfizer by 29.9% during the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock valued at $6,325,000 after purchasing an additional 57,188 shares during the last quarter. Penn Davis Mcfarland Inc. boosted its position in Pfizer by 50.9% during the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after purchasing an additional 57,777 shares during the last quarter. Finally, Mackenzie Financial Corp boosted its position in Pfizer by 119.6% during the third quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock valued at $79,157,000 after purchasing an additional 1,691,773 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several brokerages recently commented on PFE. Bank of America reduced their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research report on Thursday, February 12th. Morgan Stanley increased their price target on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research report on Friday, April 10th. Citigroup increased their price target on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research report on Wednesday, April 29th. Finally, CICC Research started coverage on Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $28.84.
Key Stories Impacting Pfizer
Here are the key news stories impacting Pfizer this week:
- Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.
- Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.
- Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.
- Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.
- Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.
Pfizer Stock Performance
PFE opened at $25.31 on Friday. Pfizer Inc. has a 12-month low of $22.45 and a 12-month high of $28.75. The stock has a market cap of $144.25 billion, a price-to-earnings ratio of 19.32 and a beta of 0.35. The business has a 50 day moving average of $26.98 and a 200-day moving average of $26.19. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.
Pfizer (NYSE:PFE – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period last year, the firm posted $0.92 earnings per share. The business’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.
Pfizer Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.
Pfizer Profile
Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
Featured Stories
- Five stocks we like better than Pfizer
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
